Icaritin - Shenogen Pharma
Alternative Names: IC-162; SNG 162Latest Information Update: 20 Feb 2025
At a glance
- Originator Shenogen Pharma
- Developer Chinese Academy of Medical Sciences; Shenogen Pharma
- Class Antineoplastics; Benzopyrans; Flavonoids; Phenyl ethers; Small molecules
- Mechanism of Action Estrogen receptor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Discontinued Breast cancer; Solid tumours
Most Recent Events
- 13 Feb 2025 Sir Run Run Shaw Hospital plans a phase III trial for Pancreatic ductal carcinoma (Late-stage disease, Metastatic disease, First-line therapy), in China (PO, Capsule), in March 2025 (NCT06825546)
- 20 Jun 2023 Shenogen Pharma in collaboration with Zhejiang Cancer Hospital plans a phase II trial for Liver cancer(Combination therapy) (PO, Capsule) (NCT05903456)
- 25 May 2023 Chemical structure information added